Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. AWK
9. ACN
10. USO

Go back to Aclaris Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Clinical and Commercial Developments

Aclaris Therapeutics (ACRS) Reports In-Line Q4 EPS, Revenues Beat

March 18, 2019 7:08 AM EDT

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.99), in-line with the analyst estimate of ($0.99). Revenue for the quarter came in at $3.67 million versus the consensus estimate of $3.24 million.

"On the commercial side of the company, we made a change in leadership as we focus on the relaunch of RHOFADE in 2019. Our development stage pipeline continues to advance with multiple data read outs expected during the course of the year across both our JAK... More